Assessment Tools to Measure Impact of Dermatologic and Mucosal Adverse Eventsa


Get Permission

aEditor’s Note: References to these tools are provided for educational purposes only. Terms of use for these tools may vary and some may be subject to copyright restrictions.

Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)

Patient Completed mcAEs Specific Symptom Experience Diary for Targeted Therapies

FACT-EGFRI-18

Skindex-16 and Hair Specific Skindex-29

HFS-14

mIAS Scale


Related Articles

How to Measure the Impact of Dermatologic and Mucosal Adverse Events on Symptom Burden and Quality of Life

Targeted anticancer therapies like epidermal growth factor receptor (EGFR) inhibitors, multitargeted tyrosine kinase inhibitors (mTKIs), and mammalian target of rapamycin (mTOR) inhibitors frequently result in dermatologic adverse events and mucosal adverse events, or, taken together, mucocutaneous ...


Advertisement

Advertisement



Advertisement